FI943430A - Lääkkeenantojärjestelmä entsyymeillä ja valolle aktivoitavien lääkkeiden samanaikaiseksi vapauttamiseksi - Google Patents

Lääkkeenantojärjestelmä entsyymeillä ja valolle aktivoitavien lääkkeiden samanaikaiseksi vapauttamiseksi Download PDF

Info

Publication number
FI943430A
FI943430A FI943430A FI943430A FI943430A FI 943430 A FI943430 A FI 943430A FI 943430 A FI943430 A FI 943430A FI 943430 A FI943430 A FI 943430A FI 943430 A FI943430 A FI 943430A
Authority
FI
Finland
Prior art keywords
drug
attached
copolymeric
carrier
anticancer
Prior art date
Application number
FI943430A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI943430A0 (fi
Inventor
Jindrich Kopecek
Nancy Krinick
Original Assignee
Univ Utah
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Utah filed Critical Univ Utah
Publication of FI943430A0 publication Critical patent/FI943430A0/fi
Publication of FI943430A publication Critical patent/FI943430A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/811—Peptides or proteins is immobilized on, or in, an inorganic carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer
    • Y10S530/816—Attached to the carrier via a bridging agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Processing Of Solid Wastes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
FI943430A 1992-01-21 1994-07-20 Lääkkeenantojärjestelmä entsyymeillä ja valolle aktivoitavien lääkkeiden samanaikaiseksi vapauttamiseksi FI943430A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/822,924 US5258453A (en) 1992-01-21 1992-01-21 Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
PCT/US1993/000683 WO1993014142A1 (en) 1992-01-21 1993-01-21 Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light

Publications (2)

Publication Number Publication Date
FI943430A0 FI943430A0 (fi) 1994-07-20
FI943430A true FI943430A (fi) 1994-09-20

Family

ID=25237341

Family Applications (1)

Application Number Title Priority Date Filing Date
FI943430A FI943430A (fi) 1992-01-21 1994-07-20 Lääkkeenantojärjestelmä entsyymeillä ja valolle aktivoitavien lääkkeiden samanaikaiseksi vapauttamiseksi

Country Status (14)

Country Link
US (1) US5258453A (hu)
EP (1) EP0621880B1 (hu)
JP (1) JPH08500327A (hu)
KR (1) KR100217186B1 (hu)
AT (1) ATE184201T1 (hu)
AU (1) AU663167B2 (hu)
CA (1) CA2128330A1 (hu)
DE (1) DE69326322T2 (hu)
DK (1) DK0621880T3 (hu)
FI (1) FI943430A (hu)
HU (1) HUT68082A (hu)
PL (1) PL172184B1 (hu)
RU (1) RU94038047A (hu)
WO (1) WO1993014142A1 (hu)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5474765A (en) * 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
US5482719A (en) * 1992-10-30 1996-01-09 Guillet; James E. Drug delivery systems
US20040071637A1 (en) * 1993-04-27 2004-04-15 Elia James P. Method for repairing a damaged portion of a human organ
US5449720A (en) * 1993-05-24 1995-09-12 Biotech Australia Pty Limited Amplification of the VB12 uptake system using polymers
GB9320781D0 (en) * 1993-10-08 1993-12-01 Erba Carlo Spa Polymer-bound camptothecin derivatives
US5444650A (en) * 1994-01-25 1995-08-22 Nippondenso Co., Ltd. Semiconductor programmable read only memory device
US5599831A (en) * 1994-05-27 1997-02-04 Poretz; Ronald D. Method of preparation of pharmaceutical compositions
NO180167C (no) * 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
CA2215978A1 (en) * 1995-04-04 1996-10-10 Wound Healing Of Oklahoma Cancer treatment by photodynamic therapy, in combination with an immunoadjuvant
US6316007B1 (en) 1995-04-04 2001-11-13 Wound Healing Of Oklahoma Combined physical and immunotherapy for cancer
US5776925A (en) * 1996-01-25 1998-07-07 Pharmacyclics, Inc. Methods for cancer chemosensitization
US6375930B2 (en) 1996-06-04 2002-04-23 Board Of Regents, The University Of Texas System Membrane incorporation of texaphyrins
US6493570B1 (en) 1998-11-02 2002-12-10 Photogen, Inc. Method for improved imaging and photodynamic therapy
WO1999002139A1 (en) * 1997-07-10 1999-01-21 Keith Baker Methods for universally distributing therapeutic agents to the brain
US6251866B1 (en) * 1997-08-05 2001-06-26 Watson Laboratories, Inc. Conjugates targeted to the interleukin-2 receptor
WO1999007324A2 (en) * 1997-08-05 1999-02-18 Watson Pharmaceuticals, Inc. Conjugates targeted to the interleukin-2 receptor
US8974363B2 (en) 1997-12-11 2015-03-10 Provectus Pharmatech, Inc. Topical medicaments and methods for photodynamic treatment of disease
DE69941447D1 (de) 1998-01-05 2009-11-05 Univ Washington Erhöhter transport unter benutzung membranzerstörender stoffe
US6087952A (en) * 1998-03-06 2000-07-11 Mobile Information Systems, Inc. Remote mobile data suite and method
US6223071B1 (en) * 1998-05-01 2001-04-24 Dusa Pharmaceuticals Inc. Illuminator for photodynamic therapy and diagnosis which produces substantially uniform intensity visible light
US20030223978A1 (en) * 1998-05-22 2003-12-04 Nabi Ivan R. Conjugates of an AMF ligand and a cytotoxic molecule for use in cancer therapy
US8557298B2 (en) 1998-08-06 2013-10-15 Provectus Pharmatech, Inc. Medicaments for chemotherapeutic treatment of disease
US6986740B2 (en) * 1998-11-02 2006-01-17 Xantech Pharmaceuticals, Inc. Ultrasound contrast using halogenated xanthenes
US6222093B1 (en) * 1998-12-28 2001-04-24 Rosetta Inpharmatics, Inc. Methods for determining therapeutic index from gene expression profiles
US20030114366A1 (en) * 1999-01-11 2003-06-19 Francis J. Martin Microfabricated particles and method for treating solid tumors
GB9905911D0 (en) 1999-03-15 1999-05-05 Photocure As Method
AU1820400A (en) * 1999-11-17 2001-05-30 School Of Pharmacy, University Of London, The Conjugates of hpma copolymer and ellipticin
US7737108B1 (en) * 2000-01-07 2010-06-15 University Of Washington Enhanced transport using membrane disruptive agents
US6455073B1 (en) 2000-07-10 2002-09-24 Enzrel, Inc. Covalent microparticle-drug conjugates for biological targeting
US6454790B1 (en) * 2000-07-21 2002-09-24 Ceramoptec Industries, Inc. Treatment for Barrett's syndrome
CZ301427B6 (cs) 2000-11-29 2010-02-24 Pci Biotech As Zpusob zavedení molekuly do cytosolu bunky
EP1343531A2 (en) * 2000-12-21 2003-09-17 McGILL UNIVERSITY Conjugates of antibodies and anticancer drugs
US7629309B2 (en) * 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7396811B2 (en) * 2001-04-30 2008-07-08 Zystor Therapeutics, Inc. Subcellular targeting of therapeutic proteins
US20040234497A1 (en) * 2001-05-04 2004-11-25 Yi Luo Hyaluronic acid containing bioconjugates:targeted delivery of anti-cancer drugs to cancer cells
AU2002332637A1 (en) * 2001-08-22 2003-03-10 Watson Pharmaceuticals, Inc. Conjugates targeted to target receptors
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
AU2002351388A1 (en) * 2001-12-14 2003-06-30 The University Of Wyoming Methods and compositions for controlled release of drugs
US6846311B2 (en) * 2002-04-02 2005-01-25 Acueity, Inc. Method and apparatus for in VIVO treatment of mammary ducts by light induced fluorescence
CA2483696A1 (en) * 2002-05-06 2003-11-20 University Of Utah Research Foundation Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents
CA2500713C (en) 2002-10-04 2012-07-03 Photokinetix, Inc. Photokinetic delivery of biologically active substances using pulsed incoherent light
EP1716232B9 (en) * 2004-02-10 2010-10-13 ZyStor Therapeutics , Inc. Acid alpha-glucosidase and fragments thereof
ES2641570T3 (es) * 2004-03-31 2017-11-10 University Of Utah Research Foundation Sistemas de suministro macromoleculares para imagenología no invasiva, evaluación y tratamiento de artritis y otras enfermedades inflamatorias
US20070287680A1 (en) * 2004-05-10 2007-12-13 University Of Utah Research Foundation Combined Active and Passive Targeting of Biologically Active Agents
US20090209508A1 (en) * 2005-05-16 2009-08-20 Universite De Geneve Compounds for Photochemotherapy
US7465312B2 (en) 2006-05-02 2008-12-16 Green Medical, Inc. Systems and methods for treating superficial venous malformations like spider veins
US20090326435A1 (en) * 2006-05-02 2009-12-31 Green Medical, Inc. Systems and methods for treating superficial venous malformations like varicose or spider veins
WO2007130465A2 (en) * 2006-05-02 2007-11-15 Green Medical, Inc. Systems and methods for treating superficial venous malformations like spider veins
AU2007256780B2 (en) 2006-06-02 2013-08-29 President And Fellows Of Harvard College Protein surface remodeling
WO2007143209A2 (en) * 2006-06-02 2007-12-13 University Of Virginia Patent Foundation Luminescent diketonate polymers
GB0618524D0 (en) 2006-09-20 2006-11-01 Isis Innovation Multimeric particles
AU2007322123A1 (en) * 2006-11-13 2008-05-29 Biomarin Pharmaceutical Inc. Methods for treating Pompe disease
HUE034850T2 (hu) 2008-05-07 2018-03-28 Biomarin Pharm Inc Lizoszomális targetáló peptidek és alkalmazásuk
AU2009302387B2 (en) * 2008-10-07 2014-12-04 Rexahn Pharmaceuticals, Inc HPMA - docetaxel or gemcitabine conjugates and uses therefore
KR20100083632A (ko) * 2009-01-14 2010-07-22 울산대학교 산학협력단 표적 단백질 분해효소 감응형 항암제 전구체
JP2012525146A (ja) * 2009-04-28 2012-10-22 プレジデント アンド フェロウズ オブ ハーバード カレッジ 細胞透過のための過剰に荷電されたタンパク質
US8785168B2 (en) 2009-06-17 2014-07-22 Biomarin Pharmaceutical Inc. Formulations for lysosomal enzymes
CN104587484A (zh) 2009-10-13 2015-05-06 瑞沙恩医药公司 用于抗癌剂递送的聚合物系统
US8492339B2 (en) * 2009-10-26 2013-07-23 Empire Technology Development Llc Angiogenesis promoted by caged growth factors
EP2544701B1 (en) 2010-03-08 2019-08-14 University of Utah Research Foundation Polymeric drug delivery conjugates and methods of making and using thereof
CA2828605C (en) 2010-05-25 2019-01-15 Syndevrx, Inc. Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
US8883503B2 (en) 2011-06-23 2014-11-11 Indian Institute Of Technology Kanpur Hydrogel scaffolds for tissue engineering
CA2851344C (en) 2011-09-05 2017-10-03 Hiroshi Maeda Polymer-type fluorescent molecule probe
MY191932A (en) 2012-01-20 2022-07-19 Immunophotonics Inc Chitosan-derived compositions
US11773188B2 (en) 2012-01-20 2023-10-03 Immunophotonics, Inc Chitosan-derived compositions
BR112015025892A2 (pt) 2013-04-10 2017-07-25 Syndevrx Inc inibidores de metap2 e métodos para tratar obesidade
US20190002594A1 (en) 2014-07-16 2019-01-03 Immunophotonics, Inc. Chitosan-Derived Compositions
ES2893749T3 (es) 2015-12-10 2022-02-10 Syndevrx Inc Derivados de fumagilol y polimorfos de los mismos
CA3008960A1 (en) 2016-01-11 2017-07-20 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
MX2018015916A (es) 2016-06-16 2019-03-28 Oncoselect Therapeutics Llc Compuestos de porfirina y composiciones útiles para el tratamiento de cáncer.
JP7136807B2 (ja) 2017-04-17 2022-09-13 ザ・ユニバーシティ・オブ・シカゴ ヒトの健康及び疾患の治療用途向けの短鎖脂肪酸の腸への送達用ポリマー材料
JP6894747B2 (ja) * 2017-04-19 2021-06-30 キヤノン株式会社 重合体
CN113453721A (zh) 2018-10-26 2021-09-28 辛德弗雷克斯公司 Metap2抑制剂的生物标志物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3381105D1 (de) * 1982-08-12 1990-02-22 Kanegafuchi Chemical Ind Aktivierung biovertraeglicher terpolymere mit biologischen stoffen, deren anzubindende komplemente pathologische effektoren sind.
GB8500209D0 (en) * 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs
EP0213811A3 (en) * 1985-08-16 1987-09-09 Johnson Matthey, Inc., Bateriocin-targeted compounds for cancer therapy

Also Published As

Publication number Publication date
AU3593093A (en) 1993-08-03
EP0621880B1 (en) 1999-09-08
CA2128330A1 (en) 1993-07-22
US5258453A (en) 1993-11-02
AU663167B2 (en) 1995-09-28
WO1993014142A1 (en) 1993-07-22
DE69326322D1 (de) 1999-10-14
DK0621880T3 (da) 1999-12-20
DE69326322T2 (de) 2000-02-17
KR100217186B1 (ko) 1999-09-01
HUT68082A (en) 1995-05-29
JPH08500327A (ja) 1996-01-16
FI943430A0 (fi) 1994-07-20
EP0621880A1 (en) 1994-11-02
HU9402142D0 (en) 1994-09-28
ATE184201T1 (de) 1999-09-15
EP0621880A4 (en) 1995-04-19
PL172184B1 (pl) 1997-08-29
RU94038047A (ru) 1996-06-10

Similar Documents

Publication Publication Date Title
FI943430A (fi) Lääkkeenantojärjestelmä entsyymeillä ja valolle aktivoitavien lääkkeiden samanaikaiseksi vapauttamiseksi
Aoshima et al. N 4-behenoyl-1-β-D-arabinofuranosylcytosine as a potential new antitumor agent
DE68918860D1 (de) Photoempfindliche mittel.
DK1137436T3 (da) Stimulering af T-celler mod selvantigener under anvendelse af CTLA-4-blokeringsmidler
CO5180590A1 (es) Derivados de camptotecina que tienen actividad anti tumores
ATE269089T1 (de) Verwendung von vitamin d derivaten zur verstärkung der wirkung von zytotoxischen stoffen
AU3468900A (en) Cyclodextrin polymers for use as drug carriers
HUT43948A (en) Emulsion compositions for dosing ionizable hydrophobic medical substances which are little soluble in water and process for preparing the same
WO2006113623A3 (en) Elimination of heterogeneous or mixed cell population in tumors
FI942878A (fi) Pyrofeoforbideja ja niiden käyttö valovaikutushoidossa
BRPI9809791B8 (pt) compostos imuno efetores de fosfato de aminoalquil glucosamina e composições compreendendo os mesmos
MXPA02006220A (es) Derivados carbamato de poli(etilenglicol) hidroliticamente degradables.
WO2004027045A3 (en) Polymer-linker-drug conjugates for targeted drug delivery
NO970990D0 (no) Implanterbare formlegemer for administrering av virkestoffer til planter
CN101820919A (zh) 用于局部药物输送的可注射聚合物-脂质共混物
WO1999022722A3 (en) Use of macrolides for the treatment of cancer and macular degeneration
CN1939316B (zh) 含阿霉素的微球及其制备方法
ES2376739T3 (es) Administración conjunta de un polisacárido con un agente quimioterapéutico para el tratamiento del cáncer
Bayley et al. Photoactivatable drugs
EP0838224A3 (en) Polymer-drug conjugates with an enzyme cleavable linker
CN109762099A (zh) 一种聚合物-抗肿瘤药物偶联物及其制备方法和用途
Říhová et al. Targetable photoactivalable drugs. 3. In vitro efficacy of polymer bound chlorin e6 toward human hepatocarcinoma cell line (PLC/PRF/5) targeted with galactosamine and to mouse splenocytes targeted with anti-Thy 1.2 antibodies
CA2382885A1 (en) Rhodamine derivatives for photodynamic diagnosis and treatment
SE8601563D0 (sv) Matrismaterial, forfarande for framstellning derav och anvendning derav
BABA et al. Effective combination of anticancer drug with its antidote for chemotherapy of hepatic metastasis